There is only one question that a manufacturer has to answer before she shouts Eureka. Can she prove it? Especially when it is a food product that claims to offer relief to two of the most widely prevalent lifestyle diseaseshigh blood pressure and high blood sugar.

Dressed in blue and white, colour coordinated with cans of Fortune Vivo oil, Bollywood actor Parineeti Chopra (whose healthy diet and lean body have also made news) promoted Vivo as an oil that offered relief to diabetes patients and wellness to the health conscious. Standing next to her, Adani Wilmar’s chief executive Atul Chaturvedi and chief operating officer Angshu Mallick looked pleased with themselves for having launched Fortune brand’s first blended oil.

A joint venture between Adani Enterprises and Singapore’s Wilmar Group, Adani Wilmar already had the status of a market leader in edible oils with about 19% of the market share in 2016. With eight pure oils sold under the Fortune brand, Fortune Vivo, the ninth one, is a blend of 20% cold-pressed unrefined sesame oil and 80% physically refined rice bran oil. It was supposed to be the company’s trump card. Because the oil combination, it claimed, was unique and could miraculously reduce high blood sugar level, improve insulin sensitivity and lower high blood pressure. It expected the new brand to add 2-3% to its existing Rs 8,883 crore revenue and later in the year said it’d invest Rs 600 crore in a new oil processing plant in Odisha.

Expectation

AdanI Wilmar expected the new brand to add 2-3% to its existing Rs 8,883 crore revenue

That was in February 2016. A year later, in January, the Ahmedabad City Civil Court pricked the claim bubble of the edible oil magnate when it said, “Fortune Vivo diabetes care oil with health claim is misleading with ambiguity, and it will affect the health of the general public.” The court ruling came in favour of the Advertising Standard Council of India (ASCI), which Adani Wilmar had dragged to court when the former called its bluff on the claims.

For those who follow the industry, the past year has seen India’s largest edible oil company slug it out with regulators and consumer watchdogs. The Food Safety and Standards Authority of India (FSSAI) has slapped Fortune Vivo with numerous notices and is now investigating multiple complaints.

The boldness of its claim, the flimsiness of its evidence and the grandeur of its marketing may have singled out Adani Wilmar but it is not the only brand staking health claims. Oil companies are increasingly adding labels with claims they cannot deliver.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?

MOST POPULAR

Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750

Subscribe
 

Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500

Subscribe
MOST POPULAR

Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120

Subscribe
 

Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50

Subscribe
 

Single Story

Instant access to this story for a year along with comment privileges.

$ 20

Subscribe

Questions?

What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at [email protected] detailing the error or queries.